James ND et al., 2016-03-19: STAMPEDE's docetaxel comparison added six cycles of docetaxel to androgen deprivation in 2,962 men with locally advanced or metastatic disease. Median survival was 81 months with docetaxel versus 71 months with standard care alone (HR 0.78), but the non-metastatic subset was underpowered and showed no significant survival difference.
there was evidence of a survival advantage for SOC + Doc (HR 0·78, 95% CI 0·66-0·93; p=0·006) with 175 deaths (143 prostate cancer; 82%), median survival 81 months (IQR 41 to not reached), and 5-year survival of 63%.
Findings (PubMed full text)
James ND et al., 2016-03-19: STAMPEDE's docetaxel comparison added six cycles of docetaxel to androgen deprivation in 2,962 men with locally advanced or metastatic disease. Median survival was 81 months with docetaxel versus 71 months with standard care alone (HR 0.78), but the non-metastatic subset was underpowered and showed no significant survival difference. Funder: 'Cancer Research UK (MRC PR08, CRUK/06/019) approved, but had no further input into, the trial design. Pfizer, Novartis, and Sanofi-Aventis approved the initial and amended trial design and participated in discussions on the progress of the trial. Representatives from these industry partners were invited to comment on' the report. Maker: Sanofi-Aventis (docetaxel); Novartis (zoledronic acid). Comparator: standard of care (ADT) alone. Non-metastatic subset: prostate-cancer-specific subHR 0.82 (95% CI 0.48-1.40; p=0.475); paper states 'all survival analyses for this subset are currently underpowered'. Study type: randomized trial.
